^
    Back
    Association details:
    Biomarker:ZNF385A overexpression
    Cancer:Hepatocellular Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Int J Mol Sci
    Title:

    ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma

    Published date:
    02/05/2023
    Excerpt:
    The results revealed that high ZNF385A and ZNF346 expression groups exhibited higher TIDE (Figure 8A,B) and T-cell exclusion scores (Figure 8C,D), indicating poor immune checkpoint inhibitors (ICI) efficacy and a shorter survival time after ICI treatment.
    DOI:
    https://doi.org/10.3390/ijms24043155